Concanamycin A  (Synonyms: Antibiotic X 4357B; Folimycin; X 4357B)

Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H⁺-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research^[1]-[5].

Concanamycin A can come from S. diastatochromogenes, as a microbial metabolite with immunomodulatory activity^[1].
Concanamycin A (100 nM; 0-20 h) results DNA fragmentation in CD4⁺ and selectively induces CD8⁺ T cells rapid cell death between normal and the immunized mice source, while CD8⁺ population in mice immunized is more sensitive^[2].
Concanamycin A (3-50 nM; 16 h) inhibits LPS-induced NO production in elicited peritoneal macrophages, but (25 nM; 7 h) doesn’t inhibit LPS-induced TNF-α production^[3].
Concanamycin A (0.01 nM-1 nM) inhibits the acidification of rat liver lysosomes (IC₅₀ =0.061 nM), and inhibits oleate incorporation into cholesteryl ester (IC₅₀ =14 nM)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Concanamycin A (15 mg/kg; i.v.; 0, 10 or 24 h prior to sacrifice) induces T cell-mediated hepatitis in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

866.09

C₄₆H₇₅NO₁₄

80890-47-7

Solid

White to off-white

C[C@H]([C@@](C[C@H]1O[C@@](O[C@H](C)[C@H]2OC(N)=O)([H])C[C@H]2O)(O[C@H](/C=C/C)[C@H]1C)O)[C@H](O)[C@@H]([C@](OC(/C(OC)=C/C(C)=C/[C@H]([C@@H](O)[C@H]3CC)C)=O)([H])[C@H](/C=C/C=C(C[C@H]([C@@H]3O)C)/C)OC)C

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Vaněk, Z., et al. Immunomodulators isolated from microorganisms. Folia Microbiol. 1991. 36:99–111.

  [2]. Togashi K, et al. Concanamycin A, a vacuolar type H(+)-ATPase inhibitor, induces cell death in activated CD8(+) CTL. Cytotechnology. 1997 Nov;25(1-3):127-35.  [Content Brief]

  [3]. Eswarappa SM, et al. Folimycin (concanamycin A) inhibits LPS-induced nitric oxide production and reduces surface localization of TLR4 in murine macrophages. Innate Immun. 2008 Feb;14(1):13-24.  [Content Brief]

  [4]. Hines IN, et al. Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARα)-deficient mice. Biol Res. 2018 Feb 15;51(1):5.  [Content Brief]

  [5]. Woo JT, et al. Isolation, characterization and biological activities of concanamycins as inhibitors of lysosomal acidification. J Antibiot (Tokyo). 1992 Jul;45(7):1108-16.  [Content Brief]